{"id":"https://openalex.org/W2014029753","doi":"https://doi.org/10.1161/circulationaha.111.029892","title":"Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension","display_name":"Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension","publication_year":2011,"publication_date":"2011-10-11","ids":{"openalex":"https://openalex.org/W2014029753","doi":"https://doi.org/10.1161/circulationaha.111.029892","mag":"2014029753","pmid":"https://pubmed.ncbi.nlm.nih.gov/21986283"},"language":"en","primary_location":{"id":"doi:10.1161/circulationaha.111.029892","doi":"https://doi.org/10.1161/circulationaha.111.029892","is_oa":false,"landing_page_url":"https://doi.org/10.1161/circulationaha.111.029892","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043389439","display_name":"David A. Calhoun","orcid":"https://orcid.org/0000-0002-0188-0172","observed_orcids":["https://orcid.org/0000-0002-0188-0172"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I140172145","display_name":"University of Connecticut","ror":"https://ror.org/02der9h97","country_code":"US","type":"education","lineage":["https://openalex.org/I140172145"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU","CH","FR","US"],"is_corresponding":false,"raw_author_name":"David A. Calhoun","raw_affiliation_strings":["From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","David A. Calhoun From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)","INSERM, CIC 9201, Paris, France (J.M.)","Novartis Pharma AG, Basel, Switzerland (G.B.)","Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","institution_ids":["https://openalex.org/I140172145","https://openalex.org/I32389192","https://openalex.org/I4390039250","https://openalex.org/I56590836"]},{"raw_affiliation_string":"Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","institution_ids":["https://openalex.org/I56590836"]},{"raw_affiliation_string":"David A. Calhoun From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)","institution_ids":["https://openalex.org/I32389192"]},{"raw_affiliation_string":"INSERM, CIC 9201, Paris, France (J.M.)","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland (G.B.)","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056816871","display_name":"William B. White","orcid":"https://orcid.org/0000-0001-8936-967X","observed_orcids":["https://orcid.org/0000-0001-8936-967X","https://orcid.org/0000-0001-7310-8491"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I140172145","display_name":"University of Connecticut","ror":"https://ror.org/02der9h97","country_code":"US","type":"education","lineage":["https://openalex.org/I140172145"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU","CH","FR","US"],"is_corresponding":false,"raw_author_name":"William B. White","raw_affiliation_strings":["From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","INSERM, CIC 9201, Paris, France (J.M.)","Novartis Pharma AG, Basel, Switzerland (G.B.)","Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)","William B. White From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","institution_ids":["https://openalex.org/I140172145","https://openalex.org/I32389192","https://openalex.org/I4390039250","https://openalex.org/I56590836"]},{"raw_affiliation_string":"Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","institution_ids":["https://openalex.org/I56590836"]},{"raw_affiliation_string":"INSERM, CIC 9201, Paris, France (J.M.)","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland (G.B.)","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)","institution_ids":[]},{"raw_affiliation_string":"William B. White From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107829974","display_name":"Henry Krum","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I140172145","display_name":"University of Connecticut","ror":"https://ror.org/02der9h97","country_code":"US","type":"education","lineage":["https://openalex.org/I140172145"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU","CH","FR","US"],"is_corresponding":false,"raw_author_name":"Henry Krum","raw_affiliation_strings":["From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","Henry Krum From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)","INSERM, CIC 9201, Paris, France (J.M.)","Novartis Pharma AG, Basel, Switzerland (G.B.)","Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","institution_ids":["https://openalex.org/I140172145","https://openalex.org/I32389192","https://openalex.org/I4390039250","https://openalex.org/I56590836"]},{"raw_affiliation_string":"Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","institution_ids":["https://openalex.org/I56590836"]},{"raw_affiliation_string":"Henry Krum From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)","institution_ids":["https://openalex.org/I32389192"]},{"raw_affiliation_string":"INSERM, CIC 9201, Paris, France (J.M.)","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland (G.B.)","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100851781","display_name":"Weinong Guo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I140172145","display_name":"University of Connecticut","ror":"https://ror.org/02der9h97","country_code":"US","type":"education","lineage":["https://openalex.org/I140172145"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU","CH","FR","US"],"is_corresponding":false,"raw_author_name":"Weinong Guo","raw_affiliation_strings":["From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","INSERM, CIC 9201, Paris, France (J.M.)","Novartis Pharma AG, Basel, Switzerland (G.B.)","Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)","Weinong Guo From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","institution_ids":["https://openalex.org/I140172145","https://openalex.org/I32389192","https://openalex.org/I4390039250","https://openalex.org/I56590836"]},{"raw_affiliation_string":"Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","institution_ids":["https://openalex.org/I56590836"]},{"raw_affiliation_string":"INSERM, CIC 9201, Paris, France (J.M.)","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland (G.B.)","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)","institution_ids":[]},{"raw_affiliation_string":"Weinong Guo From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037794163","display_name":"Georgina Bermann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I140172145","display_name":"University of Connecticut","ror":"https://ror.org/02der9h97","country_code":"US","type":"education","lineage":["https://openalex.org/I140172145"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU","CH","FR","US"],"is_corresponding":false,"raw_author_name":"Georgina Bermann","raw_affiliation_strings":["From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","Georgina Bermann From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)","INSERM, CIC 9201, Paris, France (J.M.)","Novartis Pharma AG, Basel, Switzerland (G.B.)","Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","institution_ids":["https://openalex.org/I140172145","https://openalex.org/I32389192","https://openalex.org/I4390039250","https://openalex.org/I56590836"]},{"raw_affiliation_string":"Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","institution_ids":["https://openalex.org/I56590836"]},{"raw_affiliation_string":"Georgina Bermann From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)","institution_ids":["https://openalex.org/I32389192"]},{"raw_affiliation_string":"INSERM, CIC 9201, Paris, France (J.M.)","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland (G.B.)","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065799721","display_name":"Angelo J. Trapani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I140172145","display_name":"University of Connecticut","ror":"https://ror.org/02der9h97","country_code":"US","type":"education","lineage":["https://openalex.org/I140172145"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU","CH","FR","US"],"is_corresponding":false,"raw_author_name":"Angelo Trapani","raw_affiliation_strings":["From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","Angelo Trapani From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)","Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","INSERM, CIC 9201, Paris, France (J.M.)","Novartis Pharma AG, Basel, Switzerland (G.B.)","Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","institution_ids":["https://openalex.org/I140172145","https://openalex.org/I32389192","https://openalex.org/I4390039250","https://openalex.org/I56590836"]},{"raw_affiliation_string":"Angelo Trapani From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)","institution_ids":["https://openalex.org/I32389192"]},{"raw_affiliation_string":"Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","institution_ids":["https://openalex.org/I56590836"]},{"raw_affiliation_string":"INSERM, CIC 9201, Paris, France (J.M.)","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland (G.B.)","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080343259","display_name":"Martin P. Lefkowitz","orcid":"https://orcid.org/0000-0002-8830-6316","observed_orcids":["https://orcid.org/0000-0002-8830-6316"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I140172145","display_name":"University of Connecticut","ror":"https://ror.org/02der9h97","country_code":"US","type":"education","lineage":["https://openalex.org/I140172145"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU","CH","FR","US"],"is_corresponding":false,"raw_author_name":"Martin P. Lefkowitz","raw_affiliation_strings":["From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","INSERM, CIC 9201, Paris, France (J.M.)","Martin P. Lefkowitz From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)","Novartis Pharma AG, Basel, Switzerland (G.B.)","Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","institution_ids":["https://openalex.org/I140172145","https://openalex.org/I32389192","https://openalex.org/I4390039250","https://openalex.org/I56590836"]},{"raw_affiliation_string":"Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","institution_ids":["https://openalex.org/I56590836"]},{"raw_affiliation_string":"INSERM, CIC 9201, Paris, France (J.M.)","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Martin P. Lefkowitz From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.)","institution_ids":["https://openalex.org/I32389192"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland (G.B.)","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087581609","display_name":"Jo\u00ebl M\u00e9nard","orcid":"https://orcid.org/0000-0002-4507-2839","observed_orcids":["https://orcid.org/0000-0002-4507-2839"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I140172145","display_name":"University of Connecticut","ror":"https://ror.org/02der9h97","country_code":"US","type":"education","lineage":["https://openalex.org/I140172145"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU","CH","FR","US"],"is_corresponding":false,"raw_author_name":"Jo\u00ebl M\u00e9nard","raw_affiliation_strings":["From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","INSERM, CIC 9201, Paris, France (J.M.)","Novartis Pharma AG, Basel, Switzerland (G.B.)","Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham (D.A.C.); Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.); Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.); Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.);","institution_ids":["https://openalex.org/I140172145","https://openalex.org/I32389192","https://openalex.org/I4390039250","https://openalex.org/I56590836"]},{"raw_affiliation_string":"Center of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (H.K.)","institution_ids":["https://openalex.org/I56590836"]},{"raw_affiliation_string":"INSERM, CIC 9201, Paris, France (J.M.)","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland (G.B.)","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ (W.G., A.T., M.P.L.)","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":16.6381,"has_fulltext":false,"cited_by_count":232,"citation_normalized_percentile":{"value":0.99554938,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"124","issue":"18","first_page":"1945","last_page":"1955"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11839","display_name":"Hormonal Regulation and Hypertension","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11839","display_name":"Hormonal Regulation and Hypertension","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aldosterone-synthase-inhibitors","display_name":"aldosterone synthase inhibitors","score":0.7950000166893005},{"id":"https://openalex.org/keywords/essential-hypertension","display_name":"essential hypertension","score":0.9610000252723694},{"id":"https://openalex.org/keywords/eplerenone","display_name":"eplerenone","score":0.9860000014305115},{"id":"https://openalex.org/keywords/blood-pressure-reduction","display_name":"blood pressure reduction","score":0.9010000228881836},{"id":"https://openalex.org/keywords/ambulatory-blood-pressure","display_name":"ambulatory blood pressure","score":0.9150000214576721},{"id":"https://openalex.org/keywords/adrenocorticotropic-hormone-stimulation","display_name":"adrenocorticotropic hormone stimulation","score":0.8399999737739563},{"id":"https://openalex.org/keywords/cortisol-suppression","display_name":"cortisol suppression","score":0.890999972820282},{"id":"https://openalex.org/keywords/aldosterone-excess","display_name":"aldosterone excess","score":0.7379999756813049}],"concepts":[{"id":"https://openalex.org/C2778525890","wikidata":"https://www.wikidata.org/wiki/Q184564","display_name":"Aldosterone","level":2,"score":0.8602913618087769},{"id":"https://openalex.org/C2780072264","wikidata":"https://www.wikidata.org/wiki/Q423804","display_name":"Eplerenone","level":4,"score":0.8528369069099426},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8330392241477966},{"id":"https://openalex.org/C2780249997","wikidata":"https://www.wikidata.org/wiki/Q14904983","display_name":"Aldosterone synthase","level":4,"score":0.7917171716690063},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7206739783287048},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.693221926689148},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.6826333999633789},{"id":"https://openalex.org/C149323552","wikidata":"https://www.wikidata.org/wiki/Q3090739","display_name":"Ambulatory blood pressure","level":3,"score":0.6727221012115479},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6696711778640747},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.635980486869812},{"id":"https://openalex.org/C35785553","wikidata":"https://www.wikidata.org/wiki/Q756720","display_name":"Ambulatory","level":2,"score":0.4718991219997406},{"id":"https://openalex.org/C2777097880","wikidata":"https://www.wikidata.org/wiki/Q988405","display_name":"Essential hypertension","level":3,"score":0.4445699453353882},{"id":"https://openalex.org/C2780546910","wikidata":"https://www.wikidata.org/wiki/Q185690","display_name":"Adrenocorticotropic hormone","level":3,"score":0.4351426064968109},{"id":"https://openalex.org/C2776379505","wikidata":"https://www.wikidata.org/wiki/Q422188","display_name":"Spironolactone","level":3,"score":0.36085695028305054},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.287570059299469},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2335248589515686},{"id":"https://openalex.org/C198710026","wikidata":"https://www.wikidata.org/wiki/Q898218","display_name":"Renin\u2013angiotensin system","level":3,"score":0.088055819272995},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000324","descriptor_name":"Adrenocorticotropic Hormone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000450","descriptor_name":"Aldosterone","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006728","descriptor_name":"Hormones","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006854","descriptor_name":"Hydrocortisone","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010919","descriptor_name":"Placebos","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012083","descriptor_name":"Renin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D019405","descriptor_name":"Cytochrome P-450 CYP11B2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D019405","descriptor_name":"Cytochrome P-450 CYP11B2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1161/circulationaha.111.029892","doi":"https://doi.org/10.1161/circulationaha.111.029892","is_oa":false,"landing_page_url":"https://doi.org/10.1161/circulationaha.111.029892","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"},{"id":"pmid:21986283","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21986283","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W137431462","https://openalex.org/W1963801417","https://openalex.org/W1972347346","https://openalex.org/W1976512415","https://openalex.org/W2003362011","https://openalex.org/W2005000807","https://openalex.org/W2028732654","https://openalex.org/W2032512398","https://openalex.org/W2051212684","https://openalex.org/W2064532153","https://openalex.org/W2067564810","https://openalex.org/W2069085026","https://openalex.org/W2076347631","https://openalex.org/W2077284170","https://openalex.org/W2096645292","https://openalex.org/W2098519186","https://openalex.org/W2100121238","https://openalex.org/W2116289958","https://openalex.org/W2119080429","https://openalex.org/W2124562077","https://openalex.org/W2125226019","https://openalex.org/W2132715232","https://openalex.org/W2133877420","https://openalex.org/W2143727962","https://openalex.org/W2144751334","https://openalex.org/W2148589377","https://openalex.org/W2152094259","https://openalex.org/W2156497356","https://openalex.org/W2158930864","https://openalex.org/W2164705414","https://openalex.org/W2172086404","https://openalex.org/W2179904823","https://openalex.org/W2323458614","https://openalex.org/W2328926651"],"related_works":["https://openalex.org/W2148589377","https://openalex.org/W1521917359","https://openalex.org/W2184908512","https://openalex.org/W2145807241","https://openalex.org/W2015591431","https://openalex.org/W1972849941","https://openalex.org/W2018975186","https://openalex.org/W1971094050","https://openalex.org/W2026700006","https://openalex.org/W4412391599"],"abstract_inverted_index":{"BACKGROUND:":[0],"LCI699,":[1,201],"a":[2,86,188],"novel":[3],"inhibitor":[4],"of":[5,18,88,94,138,152,162,177,183,192,220,227,237],"aldosterone":[6,97,238,248],"synthase,":[7],"reduces":[8],"serum":[9],"aldosterone,":[10],"and":[11,58,118,157,196,203,214],"may":[12],"have":[13],"benefit":[14],"in":[15,32,85,103,142,181,241],"the":[16,25,92],"treatment":[17],"hypertension.":[19,36],"METHODS":[20],"AND":[21],"RESULTS:":[22],"We":[23,37],"performed":[24,84],"first":[26],"double-blind,":[27],"randomized":[28,38],"trial":[29],"with":[30,34,100,129,149,171,209],"LCI699":[31,42,95,111,153,163,186,210],"patients":[33,40,89,245],"primary":[35,242],"524":[39],"to":[41,90,234],"0.25":[43],"mg":[44,49,54,60,66,113,121],"once":[45,50,55],"daily":[46,51,56,62,68,123,190],"(n=92),":[47],"0.5":[48,59],"(n=88),":[52],"1.0":[53,112,193],"(n=86),":[57],"twice":[61,67,122],"(n=97);":[63],"eplerenone":[64,119,158],"50":[65,120],"(n=84);":[69],"or":[70,155],"placebo":[71,130,172],"(n=77)":[72],"for":[73,96,110],"8":[74],"weeks.":[75],"Adrenocorticotropic":[76,174],"hormone":[77,175],"(250":[78],"\u03bcg":[79],"IV)":[80],"stimulation":[81,176],"testing":[82],"was":[83,179],"subset":[87],"quantify":[91],"selectivity":[93],"synthase":[98,207,239],"compared":[99,128,170],"11-\u03b2-hydroxylase.":[101],"Reductions":[102],"clinic":[104,143,213],"diastolic":[105],"blood":[106,145,168,216],"pressure":[107,146,169],"were":[108,147,198],"significant":[109],"(-7.1":[114],"mm":[115,125,132],"Hg;":[116,126],"P=0.0012)":[117],"(-7.9":[124],"P<0.0001)":[127],"(-2.6":[131],"Hg)":[133],"but":[134],"not":[135],"other":[136],"doses":[137,151,161],"LCI699.":[139],"Significant":[140],"reductions":[141],"systolic":[144],"observed":[148],"all":[150],"(P<0.005":[154],"better)":[156],"(P<0.0001).":[159],"All":[160],"significantly":[164,211],"reduced":[165],"24-hour":[166],"ambulatory":[167,215],"(P<0.01).":[173],"cortisol":[178],"suppressed":[180],"\u224820%":[182],"subjects":[184,221],"receiving":[185],"at":[187],"total":[189],"dose":[191],"mg.":[194],"Safety":[195],"tolerability":[197],"similar":[199],"among":[200],"placebo,":[202],"eplerenone.":[204],"CONCLUSIONS:":[205],"Aldosterone":[206],"inhibition":[208,240],"lowered":[212],"pressure.":[217],"A":[218],"minority":[219],"developed":[222],"blunted":[223],"adrenocorticotropic":[224],"hormone-stimulated":[225],"release":[226],"cortisol.":[228],"These":[229],"results":[230],"support":[231],"additional":[232],"research":[233],"evaluate":[235],"use":[236],"hypertension":[243],"and/or":[244],"characterized":[246],"by":[247],"excess.":[249],"Clinical":[250],"Trial":[251],"Registration-":[252],"URL:":[253],"http://www.clinicaltrials.gov.":[254],"Unique":[255],"identifier:":[256],"NCT00758524.":[257]},"counts_by_year":[{"year":2026,"cited_by_count":24},{"year":2025,"cited_by_count":16},{"year":2024,"cited_by_count":18},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":11},{"year":2018,"cited_by_count":9},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":16},{"year":2015,"cited_by_count":23},{"year":2014,"cited_by_count":29},{"year":2013,"cited_by_count":26},{"year":2012,"cited_by_count":25}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}